I’ve been looking at BOT over the last few months and their MC...

I’ve been looking at BOT over the last few months and their MC of $700m, obviously a very different product (a cream that stops excessive sweating) but they recently received FDA approval in June and have now laid out a plan via Telehealth to and traditional sales to be in market late 2025, soft launch earlier in the year.

I see us following a similar trajectory, with FDA approval we should be at a minimum, 3x our current price. $6 ✅ BOT had FDA approval priced in and that may also happen with us and it’s a low bar for approval and should easily get over the line.

Obviously, Spontan will have a higher price point and in the short term larger potential market. (I do however see a day where everyone is buying a anti-sweat cream from their local chemist)

I don’t hold BOT yet as I’ve “gone in hard” on LTP, topping up when we hit $1.45 last month.

Things are about to heat up.

DYOR GLTAH